Cardioprotection by ivabradine through heart rate reduction and beyond

Area of Science:

• Cardiology
• Pharmacology
• Cardiovascular Research

Background:

• Myocardial ischemia poses a significant clinical challenge, leading to impaired heart function and potential infarction.
• Selective bradycardic agents, such as ivabradine, primarily reduce heart rate.
• Understanding the full spectrum of ivabradine's effects is crucial for optimizing its therapeutic application.

Purpose of the Study:

• To review the experimental and clinical evidence supporting the anti-ischemic properties of ivabradine.
• To elucidate the mechanisms underlying ivabradine's cardioprotective effects, particularly those independent of heart rate reduction.

Main Methods:

• Review of existing experimental studies on myocardial ischemia and ivabradine.
• Analysis of clinical trials evaluating ivabradine's anti-anginal and cardioprotective effects.
• Examination of data regarding infarct size reduction and timing of ivabradine administration.

Main Results:

• Ivabradine improves myocardial blood flow and contractile function during ischemia.
• Clinical administration of ivabradine effectively reduces angina symptoms.
• Significant infarct size reduction by ivabradine is observed even without heart rate reduction, and during early reperfusion.

Conclusions:

• Ivabradine exhibits potent anti-ischemic and anti-anginal effects, largely mediated by heart rate reduction.
• Ivabradine possesses pleiotropic cardioprotective actions that extend beyond heart rate lowering.
• Further research is warranted to fully elucidate the mechanisms behind ivabradine's non-bradycardic protective effects.